Business Wire
22 Dec 2025, 13:00 UTC · 46w ago
Verdict
Headline takes no side. We score ASMB +0.70 — strongly bullish.
+0.70strongly bullish
More positive than 81% of ticker scores this week
Which stocks this story touches
More positive than 81% of ticker scores this week
Assembly Bio has successfully exercised a licensing option for its investigational candidates, likely providing capital and validation.
More positive than 75% of ticker scores this week
Gilead is expanding its pipeline by exclusively licensing promising HSV inhibitor programs.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 79% of relationship scores this week
[mutual] Gilead Sciences has exercised an option to exclusively license Assembly Bio's herpes simplex virus inhibitor programs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
10h ago
−39.8%
Price is moving against the score
$21.22 vs $35.26 close before publication (Dec 19) · not market-adjusted
ASMB chart →
